SCHEMBL20817915

SCHEMBL20817915

CC(C)(C)OC(=O)N1CCN(c2cn[nH]c(=O)c2Br)CC1

nearest known ligand 0.50

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ TRPC5 Q9UL62 8/20 0.50
▸ KCNH2 Q12809 1/20 0.44
▸ NR1H2 P55055 1/20 0.44
▸ SMARCA2 P51531 1/20 0.43
▸ SMARCA4 P51532 1/20 0.43
▸ PBRM1 Q86U86 1/20 0.43
▸ CKS1B P61024 1/20 0.43
▸ SKP1 P63208 1/20 0.43
▸ SKP2 Q13309 1/20 0.43
▸ ALDH1A1 P00352 1/20 0.43
▸ LMNA P02545 1/20 0.43
▸ MAPT P10636 1/20 0.43
▸ POLB P06746 1/20 0.42
▸ GPR119 Q8TDV5 2/20 0.42
▸ DDB1 Q16531 1/20 0.41
▸ CRBN Q96SW2 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20818174 0.86 NR1H2 (0.46) TRPC5NR1H2GPR119
SCHEMBL11946229 0.85 POLB (0.61) TRPC5NR1H2CKS1BSKP1SKP2
SCHEMBL20818351 0.84 KCNH2 (0.44) KCNH2NR1H2CKS1BSKP1SKP2
SCHEMBL20832042 0.83 TRPC5 (0.51) TRPC5SMARCA2SMARCA4PBRM1GPR119
SCHEMBL30476346 0.83 TRPC5 (0.51) TRPC5SMARCA2SMARCA4PBRM1GPR119
SCHEMBL20831929 0.83 TRPC5 (0.46) TRPC5POLBGPR119
SCHEMBL25275764 0.81 TRPC5 (0.60) TRPC5ALDH1A1POLB
SCHEMBL20818851 0.80 TRPC5 (0.42) TRPC5NR1H2GPR119
SCHEMBL20818796 0.80 PSEN1 (0.43) TRPC5NR1H2MAPTGPR119DDB1
SCHEMBL20831279 0.79 CCNC (0.43) NR1H2CKS1BSKP1SKP2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12435078-B2 Pyridazinones and methods of use thereof GFB (ABC), LLC (US) 2025-10-07 — — US disclosed
US-20230203028-A1 PYRIDAZINONES AND METHODS OF USE THEREOF GFB (ABC), LLC 2023-06-29 — — US disclosed
US-20230203028-A1 PYRIDAZINONES AND METHODS OF USE THEREOF GFB (ABC), LLC 2023-06-29 — — US disclosed
US-20230203028-A1 PYRIDAZINONES AND METHODS OF USE THEREOF GFB (ABC), LLC 2023-06-29 — — US disclosed
EP-3684364-A2 PYRIDAZINONES AND METHODS OF USE THEREOF Goldfinch Bio, Inc. (US) 2020-07-29 — — EP disclosed
WO-2019055966-A2 PYRIDAZINONES AND METHODS OF USE THEREOF GOLDFINCH BIO, INC. (US) 2019-03-21 — — WO disclosed
WO-2019055966-A2 PYRIDAZINONES AND METHODS OF USE THEREOF GOLDFINCH BIO, INC. (US) 2019-03-21 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230203028-A1 PYRIDAZINONES AND METHODS OF USE THEREOF PDXK, ATP6V1B1, REN TRPC5 1439/4885KCNH2 915/4885NR1H2 1189/4885
US-12435078-B2 Pyridazinones and methods of use thereof PDXK, ATP6V1B1, REN TRPC5 1439/4885KCNH2 915/4885NR1H2 1189/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback